Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
View Patent ↗The invention relates to the synthesis and complete stereochemical assignments of cytotoxic compounds such as compound 28-a and its stereoisomers: The invention further provides processes for making the compounds, their synthetic intermediates, and for methods of using the compounds and their pharmaceutical compositions for the treatment of neoplastic diseases.
1. A pharmaceutically acceptable salt or phosphate, ester, phosphate ester, or phosphonate ester of the compound of formula 28-a:
2. The pharmaceutically acceptable salt according to claim 1 , wherein the salt is a lithium, sodium, or potassium salt.
3. A compound having one of the following formulae:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 3 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 , wherein the pharmaceutically acceptable carrier comprises polyethylene glycol and saline solution.
6. The pharmaceutical composition according to claim 4 , wherein the pharmaceutical composition is present as a lyophilized powder.
7. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition according to claim 7 , wherein the pharmaceutically acceptable carrier comprises polyethylene glycol and saline solution.
9. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical composition is present as a lyophilized powder.
10. A method for treating a subject suffering from a cancer that is selected from the group consisting of pancreatic cancer, breast cancer, lung cancer, colon cancer, prostate cancer, brain cancer, ovarian cancer, and cervical cancer, comprising administering to the subject a therapeutically effective amount of a compound having one of the following formulae, or a pharmaceutically acceptable salt, thereof:
11. The method according to claim 10 , wherein the compound has the formula 28-a:
12. The method according to claim 10 , wherein the compound is administered intravenously.
13. The method according to claim 10 , wherein the dose of the compound is about 0.1 to about 30 mg/kg.
14. The method according to claim 13 , wherein the dose of the compound is about 0.1 to about 2.0 mg/kg.
15. A process for preparing a compound having formula 28-a:
comprising the steps of reacting a compound of formula 25:
with a compound of formula anti-27:
and deprotecting to give the compound having formula 28-a.
16. The process according to claim 15 , further comprising the step of isolating the compound of formula 28-a.
17. An intermediate compound having the formula 20:
18. A process for preparing an intermediate compound having the formula 20:
comprising the step of reacting a compound having the formula 6:
with a compound having the formula 7:
19. An intermediate compound having the formula 7:
20. A process for preparing an intermediate compound having the formula 7:
comprising the steps of
(a) ethylating a compound of formula 19:
to give a compound of formula x:
(b) reacting the compound of formula x with TMSCN to give and then isolating a compound of formula xi:
(c) oxidizing the compound of formula xi to give the compound of formula 7.